Roche ALK Test Gains FDA Approval as CDx for Zykadia

Jun 01, 2017

|

NEW YORK (GenomeWeb) – The US Food and Drug Administration has approved Roche's Ventana ALK (D5F3) CDx to identify best responders to Novartis' non-small cell lung cancer drug Zykadia (ceritinib).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Roche ALK Test Gains FDA Approval as CDx for Zykadia

To read the full story....

Breaking News

Somalogic Closes $121M Series A Funding

FDA Issues EUAs for Gravity Diagnostics Coronavirus Test, Sample Self-Collection Kit from RapidRona

Kantaro Biosciences Gets FDA Emergency Use Authorization for Coronavirus Antibody Test

In Brief This Week: Quest Diagnostics, Fluidigm, BD, and More

Tempus Gets CE Mark for xT Tumor Sequencing Assay

BTIG Downgrades Fulgent Genetics from Buy to Neutral

Featured White Papers

What's Popular?

European Consortium Seeks to Develop Liquid Biopsy Test for Prostate, Testicular Cancer

FDA Issues EUAs for Gravity Diagnostics Coronavirus Test, Sample Self-Collection Kit from RapidRona

BTIG Downgrades Fulgent Genetics from Buy to Neutral

Tempus Gets CE Mark for xT Tumor Sequencing Assay

Cepheid Receives CE Mark for SARS-CoV-2, Flu A/B, RSV Combination Test

Sponsorships